In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma (LGND – Research Report), with a price target of $310.00. The company’s shares closed last Thursday at $132.40.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of 8.8% and a 36.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ligand Pharma with a $226.67 average price target.
See the top stocks recommended by analysts >>
Ligand Pharma’s market cap is currently $2.19B and has a P/E ratio of 47.30. The company has a Price to Book ratio of 164.07.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Read More on LGND:
